Evidence mapPaperPMID 39651146Full record

ArticlebioRxiv : the preprint server for biology2024

Folate prevents the autism-related phenotype caused by developmental pyrethroid exposure in prairie voles.

Nilanjana Saferin, Ibrahim Haseeb, Adam M Taha, Sarah E Beecroft, Sangeetha Pillai, Asha E Neifer, Rudhasri Lakkuru, Brian P Kistler, Charlotte N Nawor, Isa Malik and 13 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Nilanjana SaferinDepartment of Neurosciences and Psychiatry, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.ORCID 0000-0001-5584-1032
Ibrahim HaseebCollege of Natural Sciences and Mathematics, University of Toledo, Toledo, OH 43606.
Adam M TahaDepartment of Pharmacology and Experimental Therapeutics, University of Toledo College of Pharmacy and Pharmaceutical Sciences, Toledo, OH, USA.ORCID 0000-0003-4266-4334
Sarah E BeecroftDepartment of Pharmacology and Experimental Therapeutics, University of Toledo College of Pharmacy and Pharmaceutical Sciences, Toledo, OH, USA.
Sangeetha PillaiCollege of Natural Sciences and Mathematics, University of Toledo, Toledo, OH 43606.
Asha E NeiferDepartment of Neurosciences and Psychiatry, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Rudhasri LakkuruDepartment of Neurosciences and Psychiatry, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Brian P KistlerDepartment of Neurosciences and Psychiatry, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Charlotte N NaworDepartment of Neurosciences and Psychiatry, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Isa MalikDepartment of Neurosciences and Psychiatry, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.ORCID 0009-0005-7634-5552
Dena HasanDepartment of Neurosciences and Psychiatry, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.ORCID 0009-0000-8023-8665
Jonathan A CarlsonDepartment of Neurosciences and Psychiatry, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.ORCID 0009-0005-0537-0785
Kareem K ZadeDepartment of Neurosciences and Psychiatry, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Sydnee P DresselDepartment of Pharmacology and Experimental Therapeutics, University of Toledo College of Pharmacy and Pharmaceutical Sciences, Toledo, OH, USA.
Eileen M CarneyDepartment of Pharmacology and Experimental Therapeutics, University of Toledo College of Pharmacy and Pharmaceutical Sciences, Toledo, OH, USA.
Radha ShahCollege of Natural Sciences and Mathematics, University of Toledo, Toledo, OH 43606.ORCID 0009-0002-4720-3297
Shudhant GautamCollege of Natural Sciences and Mathematics, University of Toledo, Toledo, OH 43606.ORCID 0009-0007-3069-3249
John VergisDepartment of Neurosciences and Psychiatry, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Kari L NeiferDepartment of Neurosciences and Psychiatry, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.ORCID 0000-0002-3691-3851
Zachary V JohnsonEmory National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, USA.
Morgan L GustisonDepartment of Psychology, The University of Western Ontario, London, ON, Canada (current); Department of Integrative Biology, University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-1162-8966
F Scott HallDepartment of Pharmacology and Experimental Therapeutics, University of Toledo College of Pharmacy and Pharmaceutical Sciences, Toledo, OH, USA.ORCID 0000-0002-0822-4063
James P BurkettDepartment of Neurosciences and Psychiatry, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.ORCID 0000-0002-6357-5499

Funding

Emory National Primate Research CenterP51OD011132 · EMORY UNIVERSITY · 2025 to 2025
$10.8M
NIEHS NIH HHS R00 ES027869NIEHS NIH HHS R21 ES036352NIH HHS P51 OD011132NIMH NIH HHS K99 MH126164
6 · The paper itself

Abstract

Neurodevelopmental disorders (NDDs) have dramatically increased in prevalence to an alarming one in six children, and yet both causes and preventions remain elusive. Recent human epidemiology and animal studies have implicated developmental exposure to pyrethroid pesticides, one of the most common classes of pesticides in the US, as an environmental risk factor for autism and neurodevelopmental disorders. Our previous research has shown that low-dose chronic developmental pyrethroid exposure (DPE) changes folate metabolites in the adult mouse brain. We hypothesize that DPE acts directly on molecular targets in the folate metabolism pathway, and that high-dose maternal folate supplementation can prevent or reduce the biobehavioral effects of DPE. We exposed pregnant prairie vole dams chronically to vehicle or low-dose deltamethrin (3 mg/kg/3 days) with or without high-dose folate supplementation (methylfolate, 5 mg/kg/3 days). The resulting DPE offspring showed broad deficits in five behavioral domains relevant to neurodevelopmental disorders (including the social domain); increased plasma folate concentrations; and increased neural expression of SHMT1, a folate cycle enzyme. Maternal folate supplementation prevented most of the behavioral phenotypes (except for repetitive behaviors) and caused potentially compensatory changes in neural expression of FOLR1 and MTHFR, two folate-related proteins. We conclude that DPE causes neurodevelopmental disorder-relevant behavioral deficits; DPE directly alters aspects of folate metabolism; and preventative interventions targeting folate metabolism are effective in reducing, but not eliminating, the behavioral effects of DPE.

Identifiers

PMID39651146
PMCPMC11623627

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.